Pharmacology · Cardiovascular

Lipid Management in Special Cardiovascular Populations

Visual summary — familial hypercholesterolemia, acute coronary syndrome, heart failure, hypertriglyceridemia, and the elderly

Familial hypercholesterolemia is massively underdiagnosed — heterozygous FH affects 1 in 250 people, but most go undetected until their first myocardial infarction in their 40s; the Dutch Lipid Clinic Network criteria and cascade screening of first-degree relatives are the tools for identification, and LDL targets are far more aggressive than for general primary prevention (below 100 mg/dL for heterozygous FH, below 70 mg/dL for those with established cardiovascular disease).
Acute coronary syndrome requires a specific lipid-lowering sequence: high-intensity statin started within 24 hours of presentation regardless of baseline LDL, reassessment at 4 to 6 weeks on high-intensity statin, and escalation to add ezetimibe if LDL remains above 70 mg/dL and then a PCSK9 inhibitor if the target is still not reached — PROVE IT-TIMI 22 and ODYSSEY OUTCOMES defined this evidence base.
Heart failure with reduced ejection fraction is the one clinical situation where statins, despite reducing LDL, produced neutral cardiovascular outcomes in dedicated trials — CORONA and GISSI-HF both showed no mortality benefit when rosuvastatin was added to guideline-directed heart failure therapy; statins are not initiated solely for heart failure but are continued if the patient has another indication.
Severe hypertriglyceridemia above 500 mg/dL shifts the primary treatment goal from cardiovascular event prevention to acute pancreatitis prevention — the immediate interventions are eliminating contributing factors (alcohol, uncontrolled diabetes, estrogen, thiazides, beta-blockers, high-fructose diet) before starting pharmacotherapy with fibrates or prescription omega-3 fatty acids.
In patients aged 75 and above, secondary prevention statins should be continued — the French national cohort study showed a 33 percent increase in cardiovascular events within two years of stopping statins at age 75; primary prevention in this age group requires individualized benefit-risk assessment accounting for frailty, comorbidities, life expectancy, and patient preference.

Abbreviations: FH = familial hypercholesterolemia · LDL = low-density lipoprotein · LDL-C = LDL cholesterol · PCSK9 = proprotein convertase subtilisin/kexin type 9 · ACS = acute coronary syndrome · MACE = major adverse cardiovascular events · HFrEF = heart failure with reduced ejection fraction · TG = triglycerides · EPA = eicosapentaenoic acid · DLCN = Dutch Lipid Clinic Network · MI = myocardial infarction

Familial Hypercholesterolemia — Diagnosis and Targets

Underdiagnosed — 1 in 250

Heterozygous FH

LDL-C typically 190–400 mg/dL from birth
Untreated: MI in men by 40s, women by 50s
Diagnosis: DLCN criteria (LDL, family history, clinical features)
Cascade screening of first-degree relatives is mandatory
LDL target: below 100 mg/dL; below 70 mg/dL with established CVD

Rare — 1 in 300,000

Homozygous FH

LDL-C typically 400–1000+ mg/dL
Untreated: MI by teenage years
Requires combination therapy: high-intensity statin + ezetimibe + PCSK9 inhibitor
Lomitapide or evinacumab for refractory cases
LDL apheresis in severe cases

Treatment sequence

FH Therapy Ladder

Step 1: High-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg)
Step 2: Add ezetimibe 10 mg
Step 3: Add PCSK9 inhibitor (evolocumab or alirocumab)
Achieved LDL below 70 mg/dL in most heterozygous patients with steps 1–3

Acute Coronary Syndrome — Lipid-Lowering Sequence

Within 24 Hours of ACS

High-intensity statin (atorvastatin 80 mg or rosuvastatin 40 mg) regardless of baseline LDL. Do not wait for lipid results. Pleiotropic effects begin immediately. PROVE IT-TIMI 22: intensive vs moderate statin → 16% reduction in MACE.

Reassess at 4–6 Weeks

Check fasting LDL on high-intensity statin. Target: below 70 mg/dL (secondary prevention); below 55 mg/dL per ESC 2019 in very high-risk. If above target: add ezetimibe 10 mg.

Reassess at 3 Months on Statin + Ezetimibe

If still above target: add PCSK9 inhibitor (alirocumab or evolocumab). ODYSSEY OUTCOMES: alirocumab post-ACS → significant MACE reduction, all-cause mortality reduction in highest-risk subgroup (LDL above 100 mg/dL).

Other Special Populations — Key Rules

Population	Statin / Lipid Therapy	Evidence and Key Rule
Heart failure (HFrEF)	Do not initiate solely for HF; continue if other indication	CORONA (rosuvastatin in HFrEF): no mortality benefit. GISSI-HF: same. Statins do not improve HF outcomes; they reduce LDL but the inflammatory and oxidative pathways driving HF are not statin-sensitive at this stage.
Severe hypertriglyceridemia (TG above 500 mg/dL)	Fibrate or prescription EPA first; statin secondary	Primary goal: prevent acute pancreatitis. First: eliminate contributing factors (alcohol, uncontrolled DM, thiazides, estrogen, beta-blockers). Then: fenofibrate or icosapentaenoic acid 4 g. Statin added once TG below 500.
Elderly age ≥75 — secondary prevention	Continue high-intensity statin	French cohort: stopping statins at 75 → 33% increase in cardiovascular events within 2 years. Greatest absolute benefit in highest-risk patients. Do not de-prescribe statins in patients with established cardiovascular disease who are tolerating therapy.
Elderly age ≥75 — primary prevention	Individualize	Benefit-risk assessment required: weigh 10-year cardiovascular risk, frailty, polypharmacy, life expectancy, and patient preference. No blanket recommendation for or against.

The "Lower is Better" Principle

Meta-analyses from the Cholesterol Treatment Trialists show a consistent 22% relative risk reduction in major cardiovascular events per 1 mmol/L (38.6 mg/dL) reduction in LDL-C, with no lower threshold of safety identified — even at LDL levels below 25 mg/dL in FOURIER and ODYSSEY OUTCOMES. The principle applies across all populations where statins have a proven indication.

Suggested References

Author / Organization	Title	Source
Katzung BG, ed.	Basic and Clinical Pharmacology. 15th ed.	McGraw-Hill; 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.	McGraw-Hill; 2023
Nordestgaard BG, Chapman MJ, Humphries SE, et al; European Atherosclerosis Society Consensus Panel.	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease.	Eur Heart J. 2013;34(45):3478–3490
Cuchel M, Bruckert E, Ginsberg HN, et al; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia.	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management.	Eur Heart J. 2014;35(32):2146–2157
Cannon CP, Braunwald E, McCabe CH, et al; PROVE IT–TIMI 22 Investigators.	Intensive versus moderate lipid lowering with statins after acute coronary syndromes.	N Engl J Med. 2004;350(15):1495–1504
Schwartz GG, Steg PG, Szarek M, et al; ODYSSEY OUTCOMES Committees and Investigators.	Alirocumab and cardiovascular outcomes after acute coronary syndrome.	N Engl J Med. 2018;379(22):2097–2107
Kjekshus J, Apetrei E, Barrios V, et al; CORONA Group.	Rosuvastatin in older patients with systolic heart failure.	N Engl J Med. 2007;357(22):2248–2261
Ginsberg HN, Packard CJ, Chapman MJ, et al.	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies.	Eur Heart J. 2021;42(47):4791–4806
Mach F, Baigent C, Catapano AL, et al.	2019 ESC/EAS Guidelines for the management of dyslipidaemias.	Eur Heart J. 2020;41(1):111–188
Giral P, Neumann A, Weill A, Coste J.	Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France.	Eur Heart J. 2019;40(43):3516–3525
Grundy SM, Stone NJ, Bailey AL, et al.	2018 AHA/ACC Guideline on the Management of Blood Cholesterol.	J Am Coll Cardiol. 2019;73(24):e285–e350
Bhatt DL, Steg PG, Miller M, et al; REDUCE-IT Investigators.	Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.	N Engl J Med. 2019;380(1):11–22
Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE.	Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management.	J Am Coll Cardiol. 2018;72(3):330–343